Windtree Therapeutics Inc ( WINT ) shares are trading lower by 20% to $2.32 during Tuesday’s session, pulling back from earlier strength, after the company announced the USPTO issued a Notice of Allowance for its patent titled “Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure.”

What Else: CEO Jed Latkin emphasized the urgent need for innovation in AHF treatment, highlighting istaroxime’s potential to improve patient outcomes. The patent strengthens Windtree's intellectual property strategy in the U.S. as it advances both early and late-stage therapies for critical conditions.

Read Also: Bitcoin Bottom Will Be $70,000 ‘At Worst,’ Arthur Hayes Says

How To Buy WINT Stock

By now you're likely curious about how to participate in the market for Windtree Therapeutics ( WINT ) – be it to purchase shares, or even attempt to bet against the company.

Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy “fractional shares,” which allows you to own portions of stock without buying an entire share.

In the case of Windtree Therapeutics ( WINT ), which is trading at $2.91 as of publishing time, $100 would buy you 34.36 shares of stock.

If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

According to data from Benzinga Pro, WINT has a 52-week high of $737.44 and a 52-week low of $2.90.